Taysha Gene Therapies, Inc.
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
TSHA | US
Overview
Corporate Details
- ISIN(s):
- US8776191061
- LEI:
- Country:
- United States of America
- Address:
- 3000 PEGASUS PARK DRIVE, 75247 DALLAS
- Website:
- https://tayshagtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS). The company utilizes adeno-associated virus (AAV)-based technologies to create potentially curative treatments for patients with rare genetic disorders that have limited or no therapeutic options. Taysha is advancing a pipeline of gene therapy programs, with a focus on conditions such as Rett syndrome. The company is committed to being an ally to the rare disease community by working to provide transformative treatments that improve patient lives.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all Taysha Gene Therapies, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Taysha Gene Therapies, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Taysha Gene Therapies, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
%20LTD/other/Cuprina_Holdings_Cayman_LTD-logo.png){kind=logo}